Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Zealand Pharma A/S has received an average consensus recommendation of "Buy" from seven brokerages, with five analysts labeling it as a "strong buy."
• The company's latest earnings report indicated earnings per share of $16.06, which fell short of analyst expectations of $16.72.
• As of the latest updates, Zealand Pharma A/S shares opened at $69.02 and have a market capitalization of $4.90 billion with a twelve-month price range between $49.98 and $136.76.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) has been given an average recommendation of "Buy" by the seven brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a buy recommendation and five have given a strong buy recommendation to the company.

A number of equities analysts have weighed in on the stock. Wells Fargo & Company upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a research report on Thursday, July 24th. Zacks Research downgraded shares of Zealand Pharma A/S from a "hold" rating to a "strong sell" rating in a research report on Friday, August 15th. Barclays upgraded Zealand Pharma A/S to a "strong-buy" rating in a report on Monday, July 7th. Finally, BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, July 1st.

Zealand Pharma A/S Price Performance

Shares of Zealand Pharma A/S stock opened at $69.02 on Friday. The firm has a market cap of $4.90 billion, a PE ratio of 4.85 and a beta of 0.73. Zealand Pharma A/S has a twelve month low of $49.98 and a twelve month high of $136.76. The company has a quick ratio of 25.07, a current ratio of 15.09 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average price of $60.13 and a 200 day moving average price of $66.01.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $16.72 by ($0.66). The business had revenue of $1.43 billion for the quarter, compared to analysts' expectations of $9.18 billion. Zealand Pharma A/S had a return on equity of 67.06% and a net margin of 73.90%. Sell-side analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.